The market's opinion of the business has improved over the past five years, reflecting a track record of earnings growth. The company's strategy appears to be drawing new investors, with an average annual return of 10% over five years.
Gainers: •$Checkmate Pharmaceuticals(CMPI.US)$+331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash) •$アクサム・セラピューティクス(AXSM.US)$+27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder) •$スーパー・マイクロ・コンピューター(SMCI.US)$+14.3% (earnings report) •$プラグパワー(PLUG.US)$+9.24% (t...
FNBに関するコメント
コラムToday's pre-market stock movers: TSLA, T, NOK, UAL and more
In reaction to earnings/guidance:
• $スーパー・マイクロ・コンピューター(SMCI.US)$ +18%,$ノキア(NOK.US)$ +7.7%,$ダナハー(DHR.US)$ +6.3%,$RLI(RLI.US)$ +5%,$CSX(CSX.US)$ +4.3%,$ラスベガス・サンズ(LVS.US)$ +4.2%,$アルコア(AA.US)$ +3.4%(also authorizes new $500 mln share repurchase program)
• $スチール・ダイナミクス(STLD.US)$ +2.8%,$ハーク・ホールディングス(HRI.US)$ +2.6%,$テスラ(TSLA.US)$ +2.5%, $フィリップ モリス インターナショナル(PM.US)$ +2.5%,$FNB(FNB.US)$ ...
コラムToday's pre-market stock movers: PLUG, CMPI, JNJ, LMT and more
• $Checkmate Pharmaceuticals(CMPI.US)$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $アクサム・セラピューティクス(AXSM.US)$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $スーパー・マイクロ・コンピューター(SMCI.US)$ +14.3% (earnings report)
• $プラグパワー(PLUG.US)$ +9.24% (t...
まだコメントはありません